<SEC-DOCUMENT>0001193125-25-162644.txt : 20250722
<SEC-HEADER>0001193125-25-162644.hdr.sgml : 20250722
<ACCEPTANCE-DATETIME>20250722170116
ACCESSION NUMBER:		0001193125-25-162644
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250716
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250722
DATE AS OF CHANGE:		20250722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39979
		FILM NUMBER:		251140890

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d24616d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vor="http://vorbiopharma.com/20250716" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-322">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-07-16_to_2025-07-16">0001817229</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="vor-20250716.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-07-16_to_2025-07-16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001817229</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-07-16</xbrli:startDate> <xbrli:endDate>2025-07-16</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-333">8-K</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt:datemonthdayyearen" id="ixv-334">July&#160;16, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-335">Vor Biopharma Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt-sec:stateprovnameen" id="ixv-336">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-337">001-39979</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-338">81-1591163</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-339">100 Cambridgepark Drive</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-340">Suite 101</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-341">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt-sec:stateprovnameen" id="ixv-342">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-343">02140</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-344">(617)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-345">655-6580</ix:nonNumeric></p> <p style="margin-top:15pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt-sec:boolballotbox" id="ixv-346">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt-sec:boolballotbox" id="ixv-347">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt-sec:boolballotbox" id="ixv-348">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt-sec:boolballotbox" id="ixv-349">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-350">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-351">VOR</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt-sec:exchnameen" id="ixv-352">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt-sec:boolballotbox" id="ixv-353">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-07-16_to_2025-07-16" format="ixt-sec:boolballotbox" id="ixv-354">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;5.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Resignation of Sven (Bill) Ante Lundberg as a Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;17, 2025, Sven (Bill) Ante Lundberg, M.D., a member of the Board of Directors (the &#8220;Board&#8221;) of Vor Biopharma Inc. (the &#8220;Company&#8221;), delivered his notice of resignation to the Board, effective immediately. Dr.&#160;Lundberg&#8217;s decision to&#160;resign&#160;was not as a result of any disagreement with the Company. The Board thanks Dr.&#160;Lundberg for his many years of leadership and service to the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Appointment of Qing Zuraw as Chief Development Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board appointed Qing Zuraw as the Company&#8217;s Chief Development Officer, effective as of July&#160;17, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&#160;Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd. from December 2022 to July 2025, where she was one of the key leaders of the successful development and execution of clinical trials for telitacicept across four key indications&#8212;systemic lupus erythematosus (SLE), Sj&#246;gren&#8217;s syndrome, myasthenia gravis (MG), and rheumatoid arthritis (RA)&#8212;culminating in regulatory approvals in China for the treatment of SLE, generalized MG and RA. Dr.&#160;Zuraw has also previously held senior leadership roles at Janssen Research&#160;&amp; Development from December 2018 to December 2022, Teva Pharmaceutical Industries Ltd. from August 2017 to December 2018, and Akebia Therapeutics, Inc. from June 2015 to July 2017, where she led global clinical development programs across rheumatology, nephrology, respiratory, and immunology. She played a key role in the U.S. FDA approval of Guselkumab for psoriatic arthritis and contributed to multiple NDA and BLA submissions across therapeutic areas. Dr.&#160;Zuraw earned her M.D. and M.B.A. from Drexel University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into an employment agreement with Dr.&#160;Zuraw, dated July&#160;17, 2025 (the &#8220;Employment Agreement&#8221;). Under the terms of the Employment Agreement, Dr.&#160;Zuraw will receive an initial annual base salary of $565,000 and will be eligible for a discretionary annual cash bonus targeted at 40% of her then-current base salary. Dr.&#160;Zuraw will also receive <span style="white-space:nowrap">a&#160;one-time&#160;signing</span> bonus of $200,000, subject to repayment if her employment terminates under certain circumstances within the first twenty-four months. In addition, on July&#160;17, 2025 Dr.&#160;Zuraw received (i)&#160;a grant of 4,373,040 options to purchase shares of the Company&#8217;s common stock pursuant to the Vor Biopharma Inc. 2023 Inducement Plan (the &#8220;Plan&#8221;) and (ii)&#160;a grant of 937,080 restricted stock units, each representing the right to receive one share of the Company&#8217;s common stock, pursuant to the Plan. In the event of termination by the Company without cause or resignation by Dr.&#160;Zuraw for good reason, Dr.&#160;Zuraw will be entitled to severance benefits, including 12 months of base salary and continued health coverage, subject to her execution of a release of claims and a post-employment <span style="white-space:nowrap">non-competition</span> agreement. If such a termination occurs in connection with a change in control, severance benefits increase to 18&#160;months of base salary, 150% of the target bonus, accelerated vesting of equity awards and 18 months of continued health coverage. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&#160;Zuraw has also entered into the Company&#8217;s standard forms of indemnification agreement and employee confidential information and invention assignment agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Employment Agreement is not complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;and</span> is incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no arrangement or understanding between Dr.&#160;Zuraw and any other person pursuant to which she was selected as an officer of the Company, and there is no family relationship between Dr.&#160;Zuraw and any of the Company&#8217;s directors or other executive officers. There are no related party transactions between Dr.&#160;Zuraw and the Company that would require disclosure under Item 404(a) of <span style="white-space:nowrap">Regulation&#160;S-K.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Appointment of Michel Detheux and Alexander (Bo) Cumbo as Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;16, 2025 the Board increased the size of the Board from eight to ten members and appointed Michel Detheux and Alexander (Bo) Cumbo to fill the resulting vacancies, to serve on the Board as independent Class&#160;I directors to serve until the Company&#8217;s 2028 annual meeting of stockholders and until their successors are duly elected and qualified. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michel Detheux, Ph.D., age 59, currently serves as President and Chief Executive Officer of iTeos Therapeutics. He <span style="white-space:nowrap">co-founded</span> iTeos in 2011 and has led the company from its preclinical origins to late-stage clinical development, financially raising $1.2&#160;billion since inception, including a NASDAQ IPO in 2020 and one of the largest upfront strategic deals ever for an early-stage asset with GlaxoSmithKline to <span style="white-space:nowrap">co-develop</span> and <span style="white-space:nowrap">co-commercialize</span> belrestotug, iTeos&#8217; differentiated anti-TIGIT antibody, in 2021. Prior to founding iTeos, he served as a Director at Ludwig Cancer Research. Dr.&#160;Detheux began his career at Ogeda (f/k/a Euroscreen) where he worked in various scientific and business development roles. Michel currently serves as Chairman of the Board at Egle Therapeutics. Dr.&#160;Detheux holds a degree of <span style="white-space:nowrap">Bio-engineer</span> and a Ph.D. in Biochemistry from Universit&#233; Catholique de Louvain, and a business certificate from Solvay Business School. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alexander (Bo) Cumbo, age 54, has served as President and Chief Executive Officer of Solid Biosciences since December 2022. Prior to that, he served as President and Chief Executive Officer of AavantiBio from October 2020 to December 2022. Prior to that, he served in roles of increasing responsibility at Sarepta Therapeutics from January 2013 to September 2020, most recently serving as Executive Vice President, Chief Commercial Officer. He currently serves as a Board Member of Climb Bio and Verve Therapeutics. Mr.&#160;Cumbo received his Bachelor of Science in Laboratory Technology from Auburn University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with their service as directors, Dr.&#160;Detheux and Mr.&#160;Cumbo will receive the Company&#8217;s standard <span style="white-space:nowrap">non-employee</span> director cash and equity compensation under its <span style="white-space:nowrap">Non-Employee</span> Directors&#8217; Compensation Policy, which is filed as Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on <span style="white-space:nowrap">Form&#160;10-Q</span> for the quarterly period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May&#160;11, 2023, as amended to date. Pursuant to the <span style="white-space:nowrap">Non-Employee</span> Directors&#8217; Compensation Policy, Dr.&#160;Detheux and Mr.&#160;Cumbo will receive a cash retainer fee of $40,000 for service as directors, payable in equal quarterly installments in arrears on the last day of each fiscal quarter, <span style="white-space:nowrap">pro-rated</span> based on the number of days served in the applicable fiscal quarter. In addition, Dr.&#160;Detheux and Mr.&#160;Cumbo received stock options to purchase 60,000 shares of the Company&#8217;s common stock on July&#160;16, 2025 and will be eligible to receive a stock option to purchase 30,000 shares of the Company&#8217;s common stock on the date of each annual stockholder meeting of the Company, beginning with the 2026 stockholder meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&#160;Detheux and Mr.&#160;Cumbo have also entered into the Company&#8217;s standard form of indemnification agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no arrangement or understanding between Dr.&#160;Detheux or Mr.&#160;Cumbo and any other person pursuant to which Dr.&#160;Detheux or Mr.&#160;Cumbo, respectively, was appointed as a member of the Board, and Dr.&#160;Detheux and Mr.&#160;Cumbo have no direct or indirect material interest in any transaction required to be disclosed pursuant to Item&#160;404(a) of <span style="white-space:nowrap">Regulation&#160;S-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;17, 2025 the Company issued a press release announcing the appointment of Dr.&#160;Zuraw as Chief Development Officer, a copy of which is furnished as Exhibit 99.1 to this report and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;21, 2025 the Company issued a press release announcing the appointments of Dr.&#160;Detheux and Mr.&#160;Cumbo to the Board, a copy of which is furnished as Exhibit 99.2 to this report and incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d24616dex101.htm">Employment Agreement, dated as of July&#160;17, 2025, by and between the Company and Qing Zuraw </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d24616dex991.htm">Press Release, dated July&#160;17, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d24616dex992.htm">Press Release, dated July&#160;21, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Date: July&#160;22, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Vor Biopharma Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jean-Paul Kress</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jean-Paul Kress</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d24616dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>E<SMALL>MPLOYMENT</SMALL> A<SMALL>GREEMENT</SMALL> </B>(the &#147;<B><I>Agreement</I></B>&#148;) is entered into on July&nbsp;17, 2025
by and between Qing Zuraw (the &#147;<B><I>Executive</I></B>&#148;) and Vor Biopharma Inc. (the &#147;<B><I>Company</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive&#146;s personal services to the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive wishes to be employed by the Company and provide personal services and certain covenants to the Company in return for certain
compensation and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, in consideration of the mutual promises and covenants contained herein, the parties agree to the
following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. <U>E<SMALL>MPLOYMENT</SMALL></U><SMALL><U></U></SMALL><U> </U><U><SMALL>BY</SMALL></U><SMALL><U></U></SMALL><U>
</U><U><SMALL>THE</SMALL></U><SMALL><U></U></SMALL><U> </U><U>C<SMALL>OMPANY</SMALL></U><SMALL></SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>
<B><U>Position</U></B><B>.</B><B> </B>Subject to the terms set forth herein, the Company agrees to employ Executive initially in the position of Chief Development Officer, and Executive hereby accepts such employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B><U>Start Date</U></B><B>.</B><B> </B>Executive&#146;s employment with the Company shall commence on the date of this Agreement,
or such other date mutually agreed to in writing by Executive and the Company. The date Executive actually commences working for the Company is referred to as Executive&#146;s &#147;<B><I>Start Date</I></B>.&#148; Prior to the Start Date or in the
event that Executive does not commence employment with the Company under this Agreement, the Company shall have no obligation to provide Executive with compensation and benefits (including, but not limited to, the &#147;Severance Benefits&#148;
stated in Section&nbsp;6.1, 6.2 or 6.3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> <B><U>Duties</U></B><B>.</B><B> </B>Executive will initially report to the Board of
Directors of the Company (the &#147;<B><I>Board</I></B>&#148;), performing such duties as are normally associated with Executive&#146;s position and such duties as are assigned to Executive from time to time, subject to the oversight and direction
of the Board or the Board&#146;s designee. During the term of Executive&#146;s employment with the Company, Executive will devote Executive&#146;s best efforts and substantially all of Executive&#146;s business time and attention to the business of
the Company. Executive shall perform Executive&#146;s duties under this Agreement principally out of her home in Wayne, Pennsylvania. In addition, Executive shall make such business trips to such places as may be necessary or advisable for the
efficient operations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> <B><U>Company Policies and Benefits</U></B><B>.</B><B> </B>The employment relationship
between the parties shall be subject to the Company&#146;s personnel policies and procedures as they may be established, interpreted, adopted, revised or deleted from time to time in the Company&#146;s sole discretion. Executive will remain eligible
to participate on the same basis as similarly-situated Executives in the Company&#146;s benefit plans in effect from time to time during Executive&#146;s employment. The Company reserves the right to change, alter, or terminate any benefit plan in
its sole discretion. Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Company&#146;s general employment policies or practices, this Agreement shall control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. <U>C<SMALL>OMPENSATION</SMALL></U><SMALL></SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B><U>Salary</U></B><B>.</B><B> </B>Executive shall receive for Executive&#146;s services to be rendered under this Agreement an
initial base salary of $565,000 on an annualized basis, subject to review and adjustment by the Company in its sole discretion, and payable subject to standard federal and state payroll withholding requirements in accordance with the Company&#146;s
standard payroll practices (&#147;<B><I>Base Salary</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B><U>Annual Discretionary Bonus</U></B><B>.</B><B>
</B>Executive will be eligible to be awarded a discretionary annual cash bonus with a target of forty percent (40%) of Executive&#146;s then-current Base Salary, subject to review and adjustment from time to time by the Company in its sole
discretion, payable subject to standard payroll withholding requirements (&#147;<B><I>Target Bonus</I></B>&#148;). Whether or not Executive is awarded any bonus will be dependent upon (a)&nbsp;the actual achievement by Executive and the Company of
the applicable individual and corporate performance goals, as determined by the Board in its sole discretion, and (b)&nbsp;Executive&#146;s continuous performance of services to the Company through the date any such bonus is paid. The bonus may be
greater or lesser than the Target Bonus and may be zero. In the event Executive&#146;s Base Salary is increased during an applicable bonus year, any bonus Executive is eligible to receive for that year (as a percentage of Executive&#146;s Base
Salary) will be calculated such that the modified Base Salary rate only applies to the period of time from the effective date of the Base Salary adjustment through the end of the applicable bonus year (and the prior Base Salary rate applies to the
period before the Base Salary adjustment). The Board will determine in its sole discretion the extent to which Executive has achieved the performance goals upon which the bonus is based and the amount of the bonus, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B><U>Signing</U></B><B><U> </U></B><B><U>Bonus</U></B><B>.</B><B> </B>Subject to Executive commencing work on the Start Date, the
Company will pay Executive cash signing bonus of $200,000 paid in two equal installments (the &#147;<B><I>Signing</I></B><B><I> </I></B><B><I>Bonus</I></B>&#148;), subject to applicable tax withholdings, with $100,000 to be paid as an advance on the
first payroll date after the Start Date and $100,000 to be paid as an advance on the first payroll date following the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Start Date. The Signing Bonus will be earned upon
Executive&#146;s continuous employment for the twenty-four (24)&nbsp;months following the Start Date. If Executive is terminated for Cause (as defined herein) or if Executive resigns without Good Reason (as defined herein) within the first
twenty-four (24)&nbsp;months after the Start Date, the bonus is not earned and therefore Executive will be required to repay the full amount of the <FONT STYLE="white-space:nowrap">pre-tax</FONT> signing bonus paid to Executive. In this instance,
Executive must repay the signing bonus within thirty (30)&nbsp;days of Executive&#146;s last day of employment. If Executive fails to timely and fully repay the Signing Bonus, the Company will be entitled to its reasonable attorneys&#146; fees and
costs incurred to recover such amount. For the avoidance of doubt, the foregoing repayment obligation will not apply in the event Executive&#146;s employment is terminated by reason of Executive&#146;s death or Disability (as defined herein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B><U>Stock</U></B><B><U> </U></B><B><U>Option</U></B><B>.</B><B> </B>As soon as practicable following the Start Date and subject
to approval of the Board, Executive will be issued an option to purchase 4,373,040 shares of the Company&#146;s common stock (the &#147;<B><I>Option</I></B>&#148;). The Option shall have an exercise price per share equal to the fair market value per
share of the Company&#146;s common stock as of the date of grant and shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">be governed in all aspects by the Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan, as
amended and restated from time to time (&#147;<B><I>Equity Incentive Plan</I></B>&#148;) and the Company&#146;s standard form of Stock Option Agreement (&#147;<B><I>Stock Option Agreement</I></B>&#148;) between Executive and the Company. The Option
shall be an incentive stock option to the extent permissible under Section&nbsp;422 of the Internal Revenue Code. The Option shall vest according to the following schedule: 25% of the shares will vest as of the one year anniversary of the date of
grant, and the remaining 75% of the shares will then vest in substantially equal installments each month thereafter over the following 36 months, subject to continuous employment with the Company through each such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B><U>RSU Award</U></B><B>.</B><B> </B>As soon as practicable following the Start Date and subject to approval of the Board,
Executive will be issued an award of 937,080 restricted stock units, each of which represents the right to receive one share of the Company&#146;s common stock (the &#147;<B><I>RSU</I></B><B><I> </I></B><B><I>Award</I></B>&#148;). The RSU Award
shall be governed in all aspects by the Equity Incentive Plan and the Company&#146;s standard form of Restricted Stock Unit Agreement between Executive and the Company. The RSU Award shall vest according to the following schedule: 25% of the shares
will vest as of August&nbsp;1, 2026, and the remaining 75% of the shares will then vest in substantially equal installments each three-month period thereafter over the following 36 months, subject to continuous employment with the Company through
each such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.6</B> <B><U>Expense Reimbursement</U></B><B>.</B><B> </B>The Company will reimburse Executive for reasonable
business expenses in accordance with the Company&#146;s standard expense reimbursement policy, as the same may be modified by the Board from time to time. The Company shall reimburse Executive for all customary and appropriate business-related
expenses actually incurred and documented in accordance with Company policy, as in effect from time to time. For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the provisions of Section&nbsp;409A of
the Internal Revenue Code of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;): (a) any such reimbursements will be paid no later than December&nbsp;31 of the year following the year in which the expense was incurred, (b)&nbsp;the amount of
expenses reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and (c)&nbsp;the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. <U>C<SMALL>ONFIDENTIAL</SMALL> I<SMALL>NFORMATION</SMALL>, I<SMALL>NVENTIONS</SMALL>,
N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-C</FONT><SMALL>OMPETITION</SMALL> <SMALL>AND</SMALL> N<SMALL>ON</SMALL>-</U></B><B><U>S<SMALL>OLICITATION</SMALL> O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL></B><SMALL></SMALL>. As a condition of
employment, Executive agrees to execute and abide by the Employee Confidential Information and Invention Assignment Agreement attached as Exhibit A (&#147;Confidential Information Agreement&#148;), which may be amended by the parties from time to
time without regard to this Agreement. The Confidential Information Agreement contains provisions that are intended by the parties to survive and do survive termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>O<SMALL>UTSIDE</SMALL> A<SMALL>CTIVITIES</SMALL> D<SMALL>URING</SMALL>
E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.</B><B> </B>Except with the prior written consent of the Company, Executive will not, while employed by the Company, undertake or engage in any other employment, occupation or
business enterprise that would interfere with Executive&#146;s responsibilities and the performance of Executive&#146;s duties hereunder, except for (i)&nbsp;reasonable time devoted to volunteer services for or on behalf of such religious,
educational, <FONT STYLE="white-space:nowrap">non-profit</FONT> and/or other charitable organization as Executive may wish to serve, (ii)&nbsp;reasonable time devoted to activities in the <FONT STYLE="white-space:nowrap">non-profit</FONT> and
business communities consistent with Executive&#146;s duties, and (iii)&nbsp;such other activities as may be specifically approved in writing by the Company. This restriction shall not, however, preclude Executive (i)&nbsp;from owning less than one
percent (1%) of the total outstanding shares of a publicly-traded company, or (ii)&nbsp;from employment or service in any capacity with a subsidiary of the Company. Executive agrees to promptly disclose to the Board her involvement in any activities
contemplated by this Section&nbsp;4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>N<SMALL>O</SMALL> C<SMALL>ONFLICT</SMALL> <SMALL>WITH</SMALL>
E<SMALL>XISTING</SMALL> O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.</B><B> </B>Executive represents that Executive&#146;s performance of all the terms of this Agreement and service as an executive of the Company do
not and will not breach any agreement or obligation of any kind made prior to Executive&#146;s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided
services. Executive has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>T<SMALL>ERMINATION</SMALL> O<SMALL>F</SMALL> E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>.
</B>The parties acknowledge that Executive&#146;s employment relationship with the Company will remain <FONT STYLE="white-space:nowrap">at-will.</FONT> Either Executive or the Company may terminate the employment relationship for any reason
whatsoever at any time, with or without cause or advance notice. The provisions in this Section govern the amount of compensation, if any, to be provided to Executive upon termination of employment and do not alter this <FONT
STYLE="white-space:nowrap">at-will</FONT> status. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.1 <U>Termination by the Company without Cause (not in connection with a</U>
<U>Change in Control)</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall have the right to terminate Executive&#146;s employment with the Company pursuant to
this Section&nbsp;6.1 at any time without &#147;Cause&#148; (as defined below) by giving notice as described in Section&nbsp;7.1 of this Agreement. A termination pursuant to Sections 6.5 or 6.6 below is not a termination without Cause for purposes
of receiving the benefits described in this Section&nbsp;6.1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If the Company terminates Executive&#146;s employment at any time
without Cause, then Executive shall be entitled to receive the Accrued Obligations (as defined below), and provided that such termination constitutes a &#147;separation from service&#148; (as defined under Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h),</FONT> without regard to any alternative definition thereunder, a &#147;<B><I>Separation from Service</I></B>&#148;) and subject to Executive&#146;s compliance with the obligations in
Section&nbsp;6.1(c) below, Executive shall also be eligible to receive the following severance benefits (the &#147;<B><I>Severance Benefits</I></B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) The Company will pay Executive an amount equal to Executive&#146;s then current Base Salary for twelve (12)&nbsp;months (the
&#147;<B><I>Severance Period</I></B>&#148;), less all applicable withholdings and deductions, and paid in equal installments beginning on the Company&#146;s first regularly-scheduled payroll date following the Release Effective Date (as defined
below), with the remaining installments occurring on the Company&#146;s regularly-scheduled payroll dates thereafter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) If Executive
timely elects continued coverage under COBRA for Executive and Executive&#146;s dependents under the Company&#146;s group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue Executive&#146;s
and her covered dependents&#146; health insurance coverage in effect for Executive (and Executive&#146;s covered dependents) on the termination date until the earliest of: (i)&nbsp;the termination of the Severance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Period; (ii)&nbsp;the date when Executive becomes eligible for substantially equivalent health insurance
coverage in connection with new employment or self-employment; or (iii)&nbsp;the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the termination date through the
earlier of (i)-(iii), (the &#147;<B><I>COBRA Payment Period</I></B>&#148;). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on Executive&#146;s behalf would result in a violation of applicable
law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay
Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding, for the remainder of the COBRA Payment Period. Nothing in
this Agreement shall deprive Executive of her rights under COBRA or ERISA for benefits under plans and policies arising under her employment by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) Executive will be paid all of the Accrued Obligations on the Company&#146;s first payroll date after Executive&#146;s date of termination
from employment or earlier if required by law. Executive shall receive the Severance Benefits pursuant to Section&nbsp;6.1(b) of this Agreement if: (i)&nbsp;by the sixtieth (60th) day following the date of Executive&#146;s Separation from Service,
Executive has signed and delivered to the Company a separation agreement containing (among other terms) an <FONT STYLE="white-space:nowrap">18-month</FONT> post-employment <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement and an
effective, general release of claims in favor of the Company and its affiliates and representatives, in a form presented by the Company (the &#147;<B><I>Release</I></B>&#148;) and which cannot be revoked in whole or part by such date (the date that
the Release can no longer be revoked is referred to as the &#147;<B><I>Release</I></B><B><I> </I></B><B><I>Effective</I></B><B><I> </I></B><B><I>Date</I></B>&#148;); (ii) if Executive holds any other positions with the Company or any affiliate,
including a position on the Board, Executive resigns such position(s) to be effective no later than the date of Executive&#146;s termination date (or such other date as requested by the Board); (iii) Executive returns all Company property;
(iv)&nbsp;Executive is in compliance with her post-termination obligations under this Agreement and the Confidential Information Agreement when any such Severance Benefits are due and payable; and (v)&nbsp;Executive complies with the terms of the
Release, including without limitation any mutual <FONT STYLE="white-space:nowrap">non-</FONT> disparagement and confidentiality provisions contained in the Release. To the extent that any of the Severance Benefits are deferred compensation under
Section&nbsp;409A of the Code, and are not otherwise exempt from the application of Section&nbsp;409A, then, if the period during which Executive may consider and sign the Release spans two calendar years, the payment of the Severance Benefits will
not be made or begin until the later calendar year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d) For purposes of this Agreement, &#147;<B><I>Accrued Obligations</I></B>&#148; are
(i)&nbsp;Executive&#146;s accrued but unpaid salary through the date of termination, (ii)&nbsp;any unreimbursed business expenses incurred by Executive payable in accordance with the Company&#146;s standard expense reimbursement policies, and
(iii)&nbsp;benefits owed to Executive under any qualified retirement plan or health and welfare benefit plan in which Executive was a participant in accordance with applicable law and the provisions of such plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(e) The Severance Benefits provided to Executive pursuant to this Section 6.1 are in lieu of, and not in addition to, any benefits to which
Executive may otherwise be entitled under any Company severance plan, policy or program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(f) Any damages caused by the termination of Executive&#146;s employment without Cause
would be difficult to ascertain; therefore, the Severance Benefits for which Executive is eligible pursuant to Section&nbsp;6.1(b) above in exchange for the Release is agreed to by the parties as liquidated damages, to serve as full compensation,
and not a penalty. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(g) For purposes of this Agreement, the term &#147;<B><I>Change in Control</I></B>&#148; shall have the meaning
provided in the Equity Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2 <U>Resignation</U><U> </U><U>by</U><U> </U><U>Executive</U><U> </U><U>for</U><U>
</U><U>Good</U><U> </U><U>Reason</U><U> </U><U>(not</U><U> </U><U>in</U><U> </U><U>connection</U><U> </U><U>with</U><U> </U><U>a</U> <U>Change in Control).</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Provided Executive has not previously been notified of the Company&#146;s intention to terminate Executive&#146;s employment, Executive
may resign from employment with the Company for Good Reason (as defined in Section&nbsp;6.2(b) below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Good
Reason</I></B>&#148; for purposes of this Agreement shall mean the occurrence of any of the following conditions without Executive&#146;s consent, after Executive&#146;s provision of written notice to the Company of the existence of such condition
(which notice must be provided as described in Section&nbsp;7.1 within thirty (30)&nbsp;days of the initial existence of the condition and must specify the particular condition in reasonable detail), provided that the Company has not first provided
notice to Executive of its intent to terminate Executive&#146;s employment: (i)&nbsp;a material reduction in Executive&#146;s Base Salary or Target Bonus opportunity (unless such reduction is part of a broad-based salary reduction applicable to the
Company&#146;s senior management); (ii) a material diminution in Executive&#146;s authority, duties or responsibilities; (iii)&nbsp;a material breach by the Company of a material term of an agreement between Executive and the Company concerning the
terms and conditions of such Executive&#146;s employment with the Company; or (iv)&nbsp;a material change in the geographic location at which the employee must perform services to the Company (it being understood that any change of forty
(40)&nbsp;or more miles would be material). Notwithstanding the foregoing, Good Reason shall only exist if the Company is provided a thirty (30)&nbsp;day period to cure the event or condition giving rise to Good Reason, and it fails to do so within
that cure period (and, additionally, Executive must resign for such Good Reason condition by giving notice as described in Section&nbsp;7.1 within thirty (30)&nbsp;days after the period for curing the violation or condition has ended). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) In the event Executive resigns from Executive&#146;s employment, then Executive shall be entitled to the Accrued Obligations and, provided
such resignation constitutes a Separation from Service and Executive complies with the obligations in Section&nbsp;6.1(c) of this Agreement (including the requirement to provide an effective Release), Executive shall also be eligible to receive the
same Severance Benefits as described in Section&nbsp;6.1 and on the same conditions as if Executive had been terminated by the Company without Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.3 <U>Termination</U><U> </U><U>by</U><U> </U><U>the</U><U> </U><U>Company</U><U> </U><U>without</U><U> </U><U>Cause</U><U>
</U><U>or</U><U> </U><U>Resignation</U><U> </U><U>by</U><U> </U><U>Executive</U> <U>for Good Reason in Connection with a Change in Control</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) In the event that the Company terminates Executive&#146;s employment without Cause (as defined below) or Executive resigns for Good Reason
within twelve (12)&nbsp;months following the effective date of a Change in Control (&#147;<B><I>Change in Control Termination Date</I></B>&#148;), then Executive shall be entitled to the Accrued Obligations and, subject to Executive&#146;s
compliance with Section&nbsp;6.1(c), including but not limited to the Release requirement and Executive&#146;s continued compliance with Executive&#146;s obligations to the Company under Executive&#146;s Confidential Information Agreement, then
Executive will be eligible for the following &#147;<B><I>Change in Control Severance Benefits</I></B>:&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) The Company will provide Executive the Severance Benefits as described in and subject
to conditions in Section&nbsp;6.1(b)(i) and Section&nbsp;6.1b(iv) above, provided that, in each case, the references to &#147;12 months&#148; shall instead refer to &#147;18 months.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) The Company will pay Executive 150% of the Target Bonus for the year in which Executive&#146;s employment terminates, payable in lump
sum. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) Effective as of Executive&#146;s Change in Control Termination Date, and provided that Company equity awards have been
continued, assumed or substituted for by the Company and/or the acquiror (or any affiliate of the acquiror) in connection with such Change in Control transaction, the vesting and exercisability of all outstanding unvested Company equity awards that
are held by Executive as of immediately prior to the Change in Control Termination Date and which are scheduled to vest and become exercisable under a time-based, performance-based or service-based schedule shall be deemed immediately vested and
exercisable as of Executive&#146;s termination date (and, for clarity, if any unvested equity award is in the form of restricted stock where the unvested shares are subject to a share reacquisition or repurchase right on behalf of the Company upon
Executive&#146;s termination from employment or service (<I>e.g.</I>, at the lower of the stock&#146;s fair market value or the original purchase price), such unvested share reacquisition or repurchase right will lapse as to the shares of stock that
otherwise are scheduled or are eligible to vest following the Change in Control Termination Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.4 <U>Termination</U><U>
</U><U>by</U><U> </U><U>the</U><U> </U><U>Company</U><U> </U><U>for</U><U> Cause</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall have the right to
terminate Executive&#146;s employment with the Company at any time for Cause by giving notice as described in Section&nbsp;7.1 of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Cause</I></B>&#148; shall mean that the Company has determined in its sole discretion that Executive has engaged in any of the
following: (i)&nbsp;a material breach of any covenant or condition under this Agreement or any other written agreement (including but not limited to restrictive covenants) between the Company and Executive; (ii)&nbsp;any commission of, or
Executive&#146;s plea of &#147;guilty&#148; or &#147;no contest&#148; to, a felony or crime involving moral turpitude under the laws of the United States or any other jurisdiction; (iii)&nbsp;gross negligence or willful misconduct in the performance
Executive&#146;s duties; (iv)&nbsp;continuing willful failure to perform assigned duties after receiving written notification of the failure from the Company; (v)&nbsp;material failure to comply with the Company&#146;s written policies; or
(vi)&nbsp;failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested such cooperation; <I>provided, however</I>, that &#147;Cause&#148; shall
not be deemed to have occurred pursuant to subsection (iii), (iv), (v) or (vi)&nbsp;hereof unless Executive has first received written notice from the Company specifying in reasonable detail the particulars of such grounds and that the Company
intends to terminate Executive&#146;s employment for such grounds, and, if curable, Executive has failed to cure such grounds to the Company&#146;s satisfaction within a period of thirty (30)&nbsp;days from the date of such notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) In the event Executive&#146;s employment is terminated at any time for Cause, Executive
will not receive Severance Benefits, Change in Control Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.5 <U>Resignation</U><U> </U><U>by</U><U> </U><U>Executive</U><U> </U><U>(other</U><U> </U><U>than</U><U> </U><U>for</U><U>
</U><U>Good</U><U> </U><U>Reason)</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Executive may resign from Executive&#146;s employment with the Company at any time by
giving notice as described in Section&nbsp;7.1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) In the event Executive resigns from Executive&#146;s employment with the Company
(other than for Good Reason), Executive will not receive Severance Benefits, Change in Control Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall
provide to Executive the Accrued Obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.6 <U>Termination</U><U> </U><U>by</U><U> </U><U>Virtue</U><U> </U><U>of</U><U>
</U><U>Death</U><U> </U><U>or Disability</U><U> </U><U>of</U><U> </U><U>Executive</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) In the event of Executive&#146;s death
while employed pursuant to this Agreement, all obligations of the parties hereunder shall terminate immediately, and the Company shall, pursuant to the Company&#146;s standard payroll policies, provide to Executive&#146;s legal representatives all
Accrued Obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Subject to applicable state and federal law, the Company shall at all times have the right, upon written notice
to Executive, to terminate this Agreement based on Executive&#146;s Disability. Termination by the Company of Executive&#146;s employment based on &#147;<B><I>Disability</I></B>&#148; shall mean termination because Executive is unable due to a
physical or mental condition to perform the essential functions of Executive&#146;s position with or without reasonable accommodation for six (6)&nbsp;months in the aggregate during any twelve (12)&nbsp;month period or based on the written
certification by two licensed physicians of the likely continuation of such condition for such period. This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other
applicable law. In the event Executive&#146;s employment is terminated based on Executive&#146;s Disability, Executive will not receive the Severance Benefits, Change in Control Severance Benefits, or any other severance compensation or benefit,
except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.7</B> <B><U>Termination Due to Discontinuance of Business</U></B><B>.</B><B> </B>Anything in this Agreement to the contrary
notwithstanding, in the event the Company&#146;s business is discontinued because rendered impracticable by substantial financial losses, lack of funding, legal decisions, administrative rulings, declaration of war, dissolution, national or local
economic depression or crisis or any reasons beyond the control of the Company, then this Agreement shall terminate as of the day the Company determines to cease operation with the same force and effect as if such day of the month were originally
set as the termination date hereof. In the event this Agreement is terminated pursuant to this Section&nbsp;6.7, Executive will not receive the Severance Benefits, Change in Control Severance Benefits, or any other compensation or benefit, except
that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.8</B> <B><U>Application</U></B><B><U> </U></B><B><U>of</U></B><B><U>
</U></B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;409A</U></B><B>.</B><B> </B>It is intended that all of the severance payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of
Section&nbsp;409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively, &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;) provided under Treasury Regulations Sections <FONT
STYLE="white-space:nowrap">1.409A-1(b)(4)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed in a manner that complies with Section&nbsp;409A. If not so exempt, this Agreement (and any definitions
hereunder) will be construed in a manner that complies with Section&nbsp;409A, and incorporates by reference all required definitions and payment terms. No severance payments will be made under this Agreement unless Executive&#146;s termination of
employment constitutes a &#147;separation from service&#148; (as defined under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)).</FONT> For purposes of Section&nbsp;409A (including, without limitation, for purposes of
Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> Executive&#146;s right to receive any installment payments under this Agreement (whether severance payments or otherwise) shall be treated as a right to
receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. To the extent that any severance payments are deferred compensation under Section&nbsp;409A,
and are not otherwise exempt from the application of Section&nbsp;409A, then, if the period during which Executive may consider and sign the Release spans two calendar years, the severance payments will not begin until the second calendar year. If
the Company determines that the Severance Benefits or Change in Control Severance Benefits provided under this Agreement constitutes &#147;deferred compensation&#148; under Section&nbsp;409A and if Executive is a &#147;specified Executive&#148; of
the Company, as such term is defined in Section&nbsp;409A(a)(2)(B)(i) of the Code at the time of Executive&#146;s Separation from Service, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under
Section&nbsp;409A, the timing of the Severance will be delayed as follows: on the earlier to occur of (a)&nbsp;the date that is six months and one day after Executive&#146;s Separation from Service, and (b)&nbsp;the date of Executive&#146;s death
(such earlier date, the &#147;<B><I>Delayed</I></B><B><I> </I></B><B><I>Initial</I></B><B><I> </I></B><B><I>Payment</I></B><B><I> </I></B><B><I>Date</I></B>&#148;), the Company will (i)&nbsp;pay to Executive a lump sum amount equal to the sum of the
Severance Benefits or Change in Control Severance Benefits that Executive would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the Severance Benefits or Change in Control Severance Benefits had
not been delayed pursuant to this Section&nbsp;6.8 and (ii)&nbsp;commence paying the balance of the Severance Benefits or Change in Control Severance Benefits in accordance with the applicable payment schedule set forth in Section&nbsp;6.1. No
interest shall be due on any amounts deferred pursuant to this Section&nbsp;6.8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.9 <U>Notice;</U><U> </U><U>Effective</U><U>
</U><U>Date</U><U> </U><U>of </U><U>Termination</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Termination of Executive&#146;s employment pursuant to this Agreement shall
be effective on the earliest of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) immediately after the Company gives notice to Executive of Executive&#146;s termination, with or
without Cause, unless pursuant to Section&nbsp;6.4(b)(vi) in which case ten (10)&nbsp;days after notice if not cured or unless the Company specifies a later date, in which case, termination shall be effective as of such later date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) immediately upon Executive&#146;s death; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) ten (10)&nbsp;days after the Company gives notice to Executive of Executive&#146;s termination on account of Executive&#146;s
Disability, unless the Company specifies a later date, in which case, termination shall be effective as of such later date, <I>provided </I>that Executive has not returned to the full-time performance of Executive&#146;s duties prior to such date;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) ten (10)&nbsp;days after Executive gives written notice to the Company of Executive&#146;s resignation, <I>provided </I>that the
Company may set a termination date at any time between the date of notice and the date of resignation, in which case Executive&#146;s resignation shall be effective as of such other date. Executive will receive compensation through any required
notice period; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) for a termination for Good Reason, immediately upon Executive&#146;s full satisfaction of the requirements of
Section&nbsp;6.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) In the event notice of a termination under subsections (a)(i) and (iii)&nbsp;is given orally, at the other
party&#146;s request, the party giving notice must provide written confirmation of such notice within five (5)&nbsp;business days of the request in compliance with the requirement of Section 7.1 below. In the event of a termination for Cause,
written confirmation shall specify the subsection(s) of the definition of Cause relied on to support the decision to terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.10</B> <B><U>Cooperation With Company After Termination of Employment</U></B><B>. </B>Following termination of Executive&#146;s
employment for any reason, Executive shall fully cooperate with the Company in all matters relating to the winding up of Executive&#146;s pending work including, but not limited to, any litigation in which the Company is involved, and the orderly
transfer of any such pending work to such other executives as may be designated by the Company. The Company will reimburse Executive for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses Executive incurs in connection with any such cooperation (excluding forgone wages, salary, or other compensation) and will make reasonable efforts to accommodate Executive&#146;s scheduling needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.11 <U>Excise Tax Adjustment</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If any payment or benefit Executive will or may receive from the Company or otherwise (a &#147;<B><I>280G Payment</I></B>&#148;) would
(i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this Section, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<B><I>Excise
Tax</I></B>&#148;), then any such 280G Payment provided pursuant to this Agreement (a &#147;<B><I>Payment</I></B>&#148;) shall be equal to the Reduced Amount. The &#147;<B><I>Reduced Amount</I></B>&#148; shall be either (x)&nbsp;the largest portion
of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax, or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause
(x)&nbsp;or by clause (y)), after taking into account all applicable federal, state, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#146;s receipt, on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence
and the Reduced Amount is determined pursuant to clause (x)&nbsp;of the preceding sentence, the reduction shall occur in the manner (the &#147;<B><I>Reduction</I></B><B><I> </I></B><B><I>Method</I></B>&#148;) that results in the greatest economic
benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#147;<B><I>Pro Rata Reduction Method</I></B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any provision of this Section&nbsp;6.11 to the contrary, the Company
will cooperate in good faith with Executive to mitigate the 280G Payment such that any such payments or benefits or a portion thereof will not be deemed an &#147;excess parachute payment&#148; within the meaning of Section&nbsp;280G of the Code.
Notwithstanding any provision of this Section&nbsp;6.11 to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section&nbsp;409A that would not
otherwise be subject to taxes pursuant to Section&nbsp;409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows:
(A)&nbsp;as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis; (B)&nbsp;as a second priority,
Payments that are contingent on future events (<I>e.g.</I>, being terminated without Cause) shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C)&nbsp;as a third priority, Payments that are &#147;deferred
compensation&#148; within the meaning of Section&nbsp;409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Unless Executive and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for
general tax compliance purposes as of the day prior to the effective date of the Change in Control transaction shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the
individual, entity, or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized accounting or law firm to make the determinations required by this Section&nbsp;6.11. The Company shall bear all expenses
with respect to the determinations by such accounting or law firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its
calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15)&nbsp;calendar days after the date on which Executive&#146;s right to a 280G Payment becomes reasonably likely to occur (if requested at
that time by Executive or the Company) or such other time as requested by Executive or the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If Executive receives a Payment
for which the Reduced Amount was determined pursuant to clause (x)&nbsp;of Section&nbsp;6.11(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive agrees to promptly return
to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x)&nbsp;of Section&nbsp;6.11(a)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was
determined pursuant to clause (y)&nbsp;of Section&nbsp;6.11(a), Executive shall have no obligation to return any portion of the Payment pursuant to the preceding sentence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. <U>G<SMALL>ENERAL</SMALL> P<SMALL>ROVISIONS</SMALL></U><SMALL></SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B><U>Notices</U></B><B>.</B><B> </B>Any notices required hereunder to be in writing shall be deemed effectively given:
(a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by electronic mail if sent during normal business hours of the recipient, and if not, then on the next business day, (c) five (5)&nbsp;days after having been sent by
registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one (1) day after deposit with a nationally recognized overnight courier, specifying <FONT STYLE="white-space:nowrap">next-day</FONT> delivery, with written
verification of receipt. All communications shall be sent to the Company at its primary office location and to Executive at Executive&#146;s address as listed on the Company payroll or to Executive&#146;s Company-issued email address or
Executive&#146;s email address as listed in Company records, or at such other address as the Company or Executive may designate by ten (10)&nbsp;days&#146; advance written notice to the other. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B><U>Severability</U></B><B>.</B><B> </B>Whenever possible, each provision of this Agreement will be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or
unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B><U>Survival</U></B><B>.</B><B> </B>Provisions of this Agreement which by their terms must survive the termination of this
Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the term, termination of Executive&#146;s employment, or otherwise, for such period as may be appropriate under the circumstances.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B><U>Waiver</U></B><B>.</B><B> </B>If either party should waive any breach of any provisions of this Agreement, it shall not
thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5</B>
<B><U>Complete Agreement</U></B><B>.</B><B> </B>This Agreement constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof. This Agreement is the complete, final, and exclusive embodiment of their
agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements. This Agreement is entered into without reliance on any promise or representation other than those expressly contained
herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company. The parties will enter into a separate Confidential Information Agreement and may enter into separate agreements related to
equity. These separate agreements govern other aspects of the relationship between the parties, have or may have provisions that survive termination of Executive&#146;s employment under this Agreement, may be amended or superseded by the parties
without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.6</B> <B><U>Counterparts</U></B><B>.</B><B> </B>This Agreement may be executed in separate counterparts, any one of which need not
contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.7</B>
<B><U>Headings</U></B><B>.</B><B> </B>The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.8</B> <B><U>Successors and Assigns</U></B><B>.</B><B> </B>The Company shall assign this
Agreement and its rights and obligations hereunder in whole, but not in part, to any Company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or substantially all of its
assets, if in any such case said Company or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto, but may not otherwise assign this
Agreement or its rights and obligations hereunder. Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to Executive&#146;s estate upon Executive&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.9</B> <B><U>Choice of Law</U></B><B>.</B><B> </B>All questions concerning the construction, validity and interpretation of this Agreement
will be governed by the laws of the State of Pennsylvania. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.10</B> <B><U>Resolution</U></B><B><U> </U></B><B><U>of</U></B><B><U>
</U></B><B><U>Disputes</U></B><B>.</B><B> </B>The parties recognize that litigation in federal or state courts or before federal or state administrative agencies of disputes arising out of Executive&#146;s employment with the Company or out of this
Agreement, or Executive&#146;s termination of employment or termination of this Agreement, may not be in the best interests of either Executive or the Company, and may result in unnecessary costs, delays, complexities, and uncertainty. The parties
agree that any dispute between the parties arising out of or relating to the negotiation, execution, performance or termination of this Agreement or Executive&#146;s employment, including, but not limited to, any claim arising out of this Agreement,
claims under Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section&nbsp;1981 of the Civil Rights Act of 1966, as
amended, the Family Medical Leave Act, the Executive Retirement Income Security Act, and any similar federal, state or local law, statute, regulation, or any common law doctrine, whether that dispute arises during or after employment, shall be
settled by binding arbitration in accordance with the Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association; <I>provided however, </I>that this dispute resolution provision shall not apply to any separate
agreements between the parties that do not themselves specify arbitration as an exclusive remedy. The location for the arbitration shall be the Boston area. Any award made by such panel shall be final, binding and conclusive on the parties for all
purposes, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The arbitrators&#146; fees and expenses and all administrative fees and expenses associated with the filing of the arbitration
shall be borne by the Company; <I>provided however</I>, that at Executive&#146;s option, Executive may voluntarily pay up to <FONT STYLE="white-space:nowrap">one-half</FONT> the costs and fees. The parties acknowledge and agree that their
obligations to arbitrate under this Section survive the termination of this Agreement and continue after the termination of the employment relationship between Executive and the Company. The parties each further agree that the arbitration provisions
of this Agreement shall provide each party with its <B>exclusive remedy</B>, and each party expressly waives any right it might have to seek redress in any other forum, except as otherwise expressly provided in this Agreement. By election
arbitration as the means for final settlement of all claims, <B>the</B><B> </B><B>parties</B><B> </B><B>hereby</B><B> </B><B>waive</B><B> </B><B>their</B><B> </B><B>respective</B><B> </B><B>rights</B><B> </B><B>to,</B><B> </B><B>and</B><B>
</B><B>agree</B><B> </B><B>not</B><B> </B><B>to,</B><B> </B><B>sue</B><B> </B><B>each</B><B> </B><B>other</B><B> </B><B>in</B><B> </B><B>any</B><B> </B><B>action in a Federal, State or local court with respect to such claims, but may seek to enforce
in court an arbitration award rendered pursuant to this Agreement.</B><B> </B><B>The parties specifically agree to waive their respective rights to a trial by jury, and further agree that no demand, request or motion will be made for trial by
jury</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties have executed this Employment Agreement on the day and year first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VOR BIOPHARMA INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jean-Paul Kress</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jean-Paul Kress</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Executive:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Qing Zuraw</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Qing Zuraw</B></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d24616dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%">


<IMG SRC="g24616g0722073319905.jpg" ALT="LOGO" STYLE="width:2.71667in;height:0.975694in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 17, 2025 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dr.&nbsp;Zuraw led clinical development of telitacicept across MG, Sj&ouml;gren&#146;s, SLE, and RA at
RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio&#146;s new development focus and execution of late-stage programs </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., July&nbsp;17, 2025 (GLOBE NEWSWIRE) &#151; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of
autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory,
and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she was one of the key leaders of successful development and execution of
clinical trials for telitacicept across four key indications&#151;systemic lupus erythematosus (SLE), Sj&ouml;gren&#146;s syndrome, myasthenia gravis (MG), and rheumatoid arthritis (RA)&#151;culminating in regulatory approvals in China for the
treatment of SLE, generalized MG and RA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At RemeGen, Dr.&nbsp;Zuraw built and led a cross-functional global team that managed all aspects of telitacicept
development, including clinical trial design, regulatory strategy, site engagement, and execution. She played a central role in regulatory interactions with the U.S. Food&nbsp;&amp; Drug Administration, European Medicines Agency, and China&#146;s
Center for Drug Evaluation, achieving Fast Track, Breakthrough Therapy, and Orphan Drug designations for telitacicept across multiple indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to welcome Qing to Vor Bio at a critical time for the company,&#148; said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman
of the Board. &#147;Her deep and diverse clinical development expertise across autoimmune and immunological diseases and with telitacicept will be invaluable as we execute on our late-stage programs. Qing&#146;s ability to lead high-performing
clinical organizations will be instrumental as we drive forward our global development programs, particularly in the U.S.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Zuraw has also
previously held senior leadership roles at Janssen Research&nbsp;&amp; Development, Teva Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Biogen Inc., and Covance, Inc., where she led global clinical development programs across
rheumatology, nephrology, respiratory, and immunology. She played a key role in the U.S. FDA approval of Guselkumab for psoriatic arthritis and contributed to multiple NDA and BLA submissions across therapeutic areas. Throughout her career, she has
built and led high-performing teams to execute complex trials from early development through post-marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Vor Bio is uniquely positioned to
become a leader in autoimmune therapeutics,&#148; said Dr.&nbsp;Zuraw. &#147;Having been intimately involved in the development of telitacicept in China from early clinical stages through to multiple approvals, I&#146;m thrilled to join the talented
team at Vor Bio to bring telitacicept to patients globally.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vor Bio </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept,
a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit <U>www.vorbio.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words &#147;aim,&#148; &#147;anticipate,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;design,&#148;
&#147;enable,&#148; &#147;expect,&#148; &#147;initiate,&#148; &#147;intend,&#148; &#147;may,&#148; <FONT STYLE="white-space:nowrap">&#147;on-track,&#148;</FONT> &#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;should,&#148;
&#147;target,&#148; &#147;update,&#148; &#147;will,&#148; &#147;would,&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking
statements in this press release include Vor Bio&#146;s statements regarding Vor Bio&#146;s development plans for telitacicept, its ability to change the treatment landscape for patients with autoimmune conditions and other statements that are not
historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption &#147;Risk Factors&#148; included in
Vor Bio&#146;s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor
Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media&nbsp;&amp; Investor Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah Spencer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap">857-242-6076</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@vorbio.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carl Mauch </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@vorbio.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>d24616dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g24616g0722072248319.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 21, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>- New board members bring
decades of experience in company building, corporate strategy, commercialization, and business development </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., July&nbsp;21, 2025
(GLOBE NEWSWIRE) &#151; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors,
effective July&nbsp;16, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alexander (Bo) Cumbo currently serves as President and Chief Executive Officer of Solid Biosciences. Prior to that, he was
the founding CEO of AavantiBio, a gene therapy company backed by Bain Capital Life Sciences, Perceptive Advisors, and RA Capital. Bo brings more than 30 years of commercial and executive leadership, including nearly eight years at Sarepta
Therapeutics, where he most recently served as Executive Vice President and Chief Commercial Officer. He played a central role in launching multiple rare disease therapies and building global commercial operations. He currently serves on the boards
of Climb Bio and Verve Therapeutics and previously served on the boards of RA Pharma and CSM through successful transactions. Mr.&nbsp;Cumbo earned a Bachelor of Science in Laboratory Technology from Auburn University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michel Detheux, Ph.D., is President and Chief Executive Officer of iTeos Therapeutics, which he <FONT STYLE="white-space:nowrap">co-founded</FONT> and led
from discovery to late-stage clinical development. Under his leadership, iTeos raised over $1&nbsp;billion in capital, completed a successful IPO, and secured a landmark $2&nbsp;billion partnership with GSK to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize the company&#146;s lead anti-TIGIT antibody. Prior to founding iTeos, Dr.&nbsp;Detheux was a Director at Ludwig Cancer Research and held scientific and business development roles
at Euroscreen (now Ogeda). He currently serves as Chairman of the Board at Egle Therapeutics. Dr.&nbsp;Detheux holds a Ph.D. in Biochemistry and a degree in Bioengineering from Universit&eacute; Catholique de Louvain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Bo and Michel are proven leaders with highly complementary experience across drug development, commercialization, and corporate strategy in cutting-edge
therapeutic areas,&#148; said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board of Vor Bio. &#147;Their insights will be invaluable as we advance telitacicept through late-stage development and expand our long-term vision to
bring transformative therapies to patients living with autoimmune disease.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Vor Bio has a unique opportunity to become a global leader in
autoimmune innovation,&#148; said Mr.&nbsp;Cumbo. &#147;I&#146;m honored to join the Board and delighted to bring my significant commercial and leadership experience to support the company&#146;s efforts to deliver potentially transformative
therapies to patients who need them.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;It&#146;s a privilege to join Vor Bio at such a critical stage in its evolution,&#148; added
Dr.&nbsp;Detheux. &#147;I look forward to contributing my knowledge and experience to help guide future strategic growth and the global clinical development of telitacicept.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vor Bio </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vor Bio is a clinical-stage biotechnology
company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious
autoantibody-driven conditions worldwide. For more information visit <U>www.vorbio.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words &#147;aim,&#148;
&#147;anticipate,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;enable,&#148; &#147;expect,&#148; &#147;initiate,&#148; &#147;intend,&#148; &#147;may,&#148;
<FONT STYLE="white-space:nowrap">&#147;on-track,&#148;</FONT> &#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;should,&#148; &#147;target,&#148; &#147;update,&#148; &#147;will,&#148; &#147;would,&#148; and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio&#146;s statements regarding Vor Bio&#146;s development
plans for telitacicept, its ability to change the treatment landscape for patients with autoimmune conditions and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in
these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements
as a result of various factors. These and other risks are described in greater detail under the caption &#147;Risk Factors&#148; included in Vor Bio&#146;s most recent annual or quarterly report and in other reports it has filed or may file with the
Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new
information, future events or otherwise, except as may be required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media&nbsp;&amp; Investor Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah Spencer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1
<FONT STYLE="white-space:nowrap">857-242-6076</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@vorbio.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carl Mauch </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@vorbio.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>vor-20250716.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 7/23/2025 12:47:18 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:vor="http://vorbiopharma.com/20250716"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://vorbiopharma.com/20250716"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vor-20250716_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vor-20250716_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>vor-20250716_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 7/23/2025 12:47:19 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>vor-20250716_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 7/23/2025 12:47:19 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="vor-20250716.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g24616g0722072248319.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g24616g0722072248319.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< 0$# 2(  A$! Q$!_\0
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MJFEVFL:?+97L8>&0<^H/8CWJY123:=T!X1XD^'^K:'*\D$3WEEG*RQ+DJ/\
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MU;8C$-^[$$@HHHKB&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g24616g0722073319905.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g24616g0722073319905.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< 0$# 2(  A$! Q$!_\0
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MJFEVFL:?+97L8>&0<^H/8CWJY123:=T!X1XD^'^K:'*\D$3WEEG*RQ+DJ/\
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MU;8C$-^[$$@HHHKB&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 16, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001817229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 16,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vor Biopharma Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1591163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cambridgepark Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">655-6580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d24616d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d24616d8k.htm">d24616d8k.htm</File>
    <File>vor-20250716.xsd</File>
    <File>vor-20250716_lab.xml</File>
    <File>vor-20250716_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d24616d8k.htm": {
   "nsprefix": "vor",
   "nsuri": "http://vorbiopharma.com/20250716",
   "dts": {
    "inline": {
     "local": [
      "d24616d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "vor-20250716.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "vor-20250716_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vor-20250716_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-07-16_to_2025-07-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d24616d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-07-16_to_2025-07-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d24616d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://vorbiopharma.com//20250716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-25-162644-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-162644-xbrl.zip
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M'D^>1K5PU(E=,.E6U?KG$\3(\[IHTH*/E_(FN/6?0!&K<)0*RS1%BHN3BCE
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M5,@U*ET-;H; B'34F, ANM/ -F&7[4H['NHK6Q51WTA9SY6@2Z);>'M<(E-
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M?]4<J,T-:4R4J"HMX7<8(C5?9,4R,OW$C@U@]*))D>=J4J<PAM"G4MVE]6R
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MTN=7Z <:K1-M>>8NCHR>HF\;S_PRT7%]XR.:F.C$C"C.WW&1-UU& BJ;EF>
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ME9HKRV;0KE0NBV8!;@AHI9D4>CLK-]"VHNGKEDVAT<7<-/!TYVD#;JOE*K!
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M0K9H.1W.,M-W)<7   Q [5[R5DJ;5]) ./#=(IJS%\-07L]:8%R"@;N0?^+
M>\9.RC$V2K(6'@4'$*)Y&F)=.X08Y8JXU[^5,3;<W/AF@RDIXG I:PZIWK7>
M/E086]"]=[2M#=Q<^Y-(A#AQ;!P86)=2*MB&UC_+.5*^U0V'6:ZWKP.-J:?
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MCD%K2WHD&$<94Y,0"%WE1,BA3^U@V6#7SY[_[K^?N/,;>[W+_BS4^_(N/M>
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MS*R#6L7#NFL"![RH47.A(4\>.-2U^UF&QU110S13U(#P]:A(3[F9<],@7,V
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M*[6E_[I0OHMF?V-'[?D?4$L#!!0    ( ">(]EK(7_FKWP0  /\M   4
M=F]R+3(P,C4P-S$V7W!R92YX;6S5FEV/XC84AN]7VO_@IC>MU) ),#L=-.R*
M,C,5ZGP)V+;JS<HD![#JV)$=!OCW/0[QED"8A=EM%7/!A^/W^/5Y'!,[N?JP
M2CAY!J69%%TO;)QY!$0D8R9F76^A?:HCQCRB,RIBRJ6 KK<&[7UX__;-U7>^
M3ZYO!P_$)_,L2W4G");+92.>,J$E7V084C<BF03$]VW]_O@C^7W37(<,@0/5
M0!*J,U#DEP7C<:=YUFR'8;/9"+=E"JB)1V*:08=<!,U6@!7/2=CLM"\ZX27I
MW9.;/(P@8Y; ME:F:\5F\XS\$/U(<M6U% (XAS6Y98**B%%.1M;R3V0@H@;I
M<4Z&1J;1IP;U#'&CB,J9^+MCWB;&/7G[AN +$RET7MKU3#J*;*PFBC>DFJ'=
MLU9@1=ZV9K4G6K9R27AY>1GD1\OU-:NJC0V$P9_W=Z-H#@GU$0)"BW::0C=Q
M]EF];>X\V!RT]37KZ#S2G8SRW!_1+7*PAOGEVVJ^*?+#IM\*&RL=>^]-DYNL
M*LEA"%-B/C\.!Y_;?)9JPF0ZIRJA^9C*\9]=A.^"C*ZDD,DZ,)K@6D:+!$1F
M/WLBOA$9R]8#,94H-CWQ2)[4SES!M.MA:-\&,W:^'V*<3Z?$R=8IGA>:)2D'
MCP1;W4D5#AV1Y;7OL* D@%4&(H;8AC'^_Z,.O]] +4:NC$H)L"=O3DQ#U)C)
MYR &9EILFR\F/>T\-?CC4U_B?-&;Z$S1*"NG@)NA(I4MY'0"O.M5B()O::B'
MW8Y-UV\YG1UK:$=4-K2-K:>B4DBJ(AL.OY:8[0_[HD:04H7Q_&B.,YQ53Y5,
M*I-3M"8KC4H5@^IZ.#_BZ>Z15#&I$#:6>&2AT8M,C6O*S3&8@E(0WVVZ?=!E
M;A&G3@UYS6^,9S,:^]@#1?D !_SJ-U@?B^F N+ZX#ABVV%K.8+/SR1C3>"RM
MLJ:^D,H^+9MSY]@\ 7K%Z3Z^QLNB4R'MB.M/:\>PQ?;.&6R;N6$(,V8Z*K('
MFAQ-K5I;7VC5?BVS"\>8X8I JE2J/+4CS##TY0*G^'5?QB<B_$*HNA/]@GT+
M^&?' -\R#@^+9 +J-)K;NKJCV_9J.5TZQFE,5X,8T\"F;+,J?0VT@T'J3O"@
M\0)GZ\PQG+TXQB3KX@-7R!">AK(R0-TQ5IJV"$/G$3:_%F'3183-?Q&ZMC8O
M>M''KX]J+)?B50"WY8[@V[9LX;FS0B]U);\4>U1/2CXSL^O[&H)[,1S!N.?;
MLFR[R?))ZHSROUAZ^NJB.H(C''=<6XKN[,N8^:2G@)["K:RI+ZFR3\O&G<T7
M<QN+/\VE.'&=MZ^K+Z-]KY:3.QLN?Z"_#$1?)LE"%,L<?2RL ^+Z$CM@V&)S
M9QME)#F+6,;$[![_C!4SUHYC5J6L+[ JMY:6.YLI3PK,D .\6LKO@YC[T.IQ
M.CU^6GPI0GWIO>2ZH-AV9P]EIS<#K1>@OIYE11QGB%9XMUS=V5@90;0P%L/F
M9,PR?O2EY+ZNOMSVO5I.[NR>C!4U#\J-ULE$'OUWMR.J+Z$=HQ:/._LC=HC=
MK*(Y%3,XY79KM;:^L*K]6F:N[8/<)*!F./9^57*9S7%^3ZDX\9&A R'J2_!%
MVQ:D.ULA17=6.(L(S8RYS>,;)U*LT-<>885GR^]_V"ZY"O;R<H<%YKGES1'S
M9I["Q9)_ %!+ 0(4 Q0    ( ">(]EINQS#>\AL  '&7   -
M  "  0    !D,C0V,39D.&LN:'1M4$L! A0#%     @ )XCV6D/<R*Z_/0
M,!$! !               ( !'1P  &0R-#8Q-F1E>#$P,2YH=&U02P$"% ,4
M    "  GB/9:>3<DS/<+  !$(@  $               @ $*6@  9#(T-C$V
M9&5X.3DQ+FAT;5!+ 0(4 Q0    ( ">(]EI'9.#*) L  #8@   0
M      "  2]F  !D,C0V,39D97@Y.3(N:'1M4$L! A0#%     @ )XCV6IGE
M^BU# P  2@L  !               ( !@7$  '9O<BTR,#(U,#<Q-BYX<V10
M2P$"% ,4    "  GB/9:/RFQH:L&  "E20  %               @ 'R=
M=F]R+3(P,C4P-S$V7VQA8BYX;6Q02P$"% ,4    "  GB/9:R%_YJ]\$  #_
M+0  %               @ '/>P  =F]R+3(P,C4P-S$V7W!R92YX;6Q02P4&
2      < !P"W 0  X(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d24616d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vor-20250716.xsd" xlink:type="simple"/>
    <context id="duration_2025-07-16_to_2025-07-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001817229</identifier>
        </entity>
        <period>
            <startDate>2025-07-16</startDate>
            <endDate>2025-07-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-322">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-07-16_to_2025-07-16"
      id="Hidden_dei_EntityCentralIndexKey">0001817229</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-333">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-334">2025-07-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-335">Vor Biopharma Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-336">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-337">001-39979</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-338">81-1591163</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-339">100 Cambridgepark Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-340">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-341">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-342">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-343">02140</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-344">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-345">655-6580</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-346">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-347">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-348">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-349">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-350">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-351">VOR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-352">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-353">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-07-16_to_2025-07-16" id="ixv-354">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
